药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02268 药明合联

休市中 05-17 16:08:17

16.960

-0.420

-2.42%

最高17.600	最低16.880	成交量500.09万
今开17.380	昨收17.380	日振幅4.14%
总市值203.11亿	流通市值203.11亿	总股本11.98亿
成交额8,560万	换手率0.42%	流通股本11.98亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02268","market":"HK","secType":"STK","nameCN":"药明合联","latestPrice":16.96,"timestamp":1715933297031,"preClose":17.38,"halted":0,"volume":5000939,"delay":0,"floatShares":1197604500,"shares":1197604500,"eps":0.29904416,"marketStatus":"休市中","marketStatusCode":7,"change":-0.42,"latestTime":"05-17 16:08:17","open":17.38,"high":17.6,"low":16.88,"amount":85597506,"amplitude":0.041427,"askPrice":16.98,"askSize":26000,"bidPrice":16.96,"bidSize":35500,"shortable":3,"etf":0,"ttmEps":0.2805262090167132,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1716168600000},"adr":0,"listingDate":1700150400000,"adjPreClose":17.38,"openAndCloseTimeList":[[1715909400000,1715918400000],[1715922000000,1715932800000]],"volumeRatio":0.5091844929622248,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02268/","defaultTab":"news","newsList":[{"id":"2435445645","title":"药明合联(02268)上涨5.06%，报17.86元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2435445645","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2435445645?lang=zh_cn&edition=full","pubTime":"2024-05-16 13:14","pubTimestamp":1715836476,"startTime":"0","endTime":"0","summary":"5月16日，药明合联(02268)盘中上涨5.06%，截至13:14，报17.86元/股，成交7823.2万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2023年年报，药明合联营业总收入21.24亿元、净利润2.84亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/16131440666480.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"1134787772","title":"通过！药明系等来8年缓冲期，公司火速回应","url":"https://stock-news.laohu8.com/highlight/detail?id=1134787772","media":"券商中国","top":-1,"share":"https://www.laohu8.com/m/news/1134787772?lang=zh_cn&edition=full","pubTime":"2024-05-16 10:30","pubTimestamp":1715826620,"startTime":"0","endTime":"0","summary":"此次通过的《法案》为5月10日公布的最新版本，内容对中国公司相比之前的版本更为缓和。在此前的华大系、药明康德及子公司基础上，新增药明生物。药明康德回复投资者表示，从2024年一季度情况来看，公司总体表现稳定。3月6日，美国参议院国土安全与政府事务委员会听证会上，参议院版的《生物安全法案》以高票通过了针对药明康德的条款后，市场担忧情绪进一步加剧。","market":"sh","thumbnail":"https://static.tigerbbs.com/24f0bdaa9acddf01d7e7aeec2b60a55e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/24f0bdaa9acddf01d7e7aeec2b60a55e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"gpt_icon":1},{"id":"2435743615","title":"南向资金5月14日净买入药明合联15.38万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2435743615","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2435743615?lang=zh_cn&edition=full","pubTime":"2024-05-16 09:31","pubTimestamp":1715823098,"startTime":"0","endTime":"0","summary":"5月14日, 南向资金增持药明合联15.38万股，连续5日增持。截止当日收盘，港股通共持有药明合联4463.28万股，占流通股3.71%。港股通增持金额前五个股分别为中国银行、中国移动、中国石油股份、中国石油化工股份、腾讯控股。药明合联近5个交易日下跌13.53%，港股通累计增持987.78万股；近20个交易日下跌7.31%，港股通累计增持1567.18万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240516094719876e5c09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240516094719876e5c09&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435561270","title":"药明合联05月14日获主力加仓2347万元 环比增加738.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2435561270","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2435561270?lang=zh_cn&edition=full","pubTime":"2024-05-14 16:15","pubTimestamp":1715674551,"startTime":"0","endTime":"0","summary":"05月14日, 药明合联股价跌1.73%，报收17.00元，成交金额2.61亿元，换手率1.24%，振幅9.13%，量比1.97。药明合联今日主力资金净流入2347万元，上一交易日主力净流入280万元，今日环比增加738.21%。该股近5个交易日下跌13.63%，主力资金累计净流入5863万元；近20日主力资金累计净流入8820万元，其中净流入天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405141616148b068bc8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405141616148b068bc8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435531309","title":"药明合联(02268)上涨5.2%，报18.2元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2435531309","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2435531309?lang=zh_cn&edition=full","pubTime":"2024-05-14 10:13","pubTimestamp":1715652836,"startTime":"0","endTime":"0","summary":"5月14日，药明合联(02268)盘中上涨5.2%，截至10:13，报18.2元/股，成交1.04亿元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2023年年报，药明合联营业总收入21.24亿元、净利润2.84亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/14101340634425.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2435539998","title":"药明合联5月13日获南向资金加仓173.10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2435539998","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2435539998?lang=zh_cn&edition=full","pubTime":"2024-05-14 09:31","pubTimestamp":1715650287,"startTime":"0","endTime":"0","summary":"5月13日, 南向资金增持药明合联173.10万股，连续4日增持。截止当日收盘，港股通共持有药明合联4447.90万股，占流通股3.70%。港股通增持金额前五个股分别为中国银行、中国移动、华润置地、招商银行、比亚迪电子。药明合联近5个交易日下跌17.22%，港股通累计增持972.40万股；近20个交易日下跌8.95%，港股通累计增持1650.15万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405140941598765558e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405140941598765558e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435395045","title":"药明合联(02268)下跌5.14%，报18.08元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2435395045","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2435395045?lang=zh_cn&edition=full","pubTime":"2024-05-13 09:54","pubTimestamp":1715565280,"startTime":"0","endTime":"0","summary":"5月13日，药明合联(02268)盘中下跌5.14%，截至09:54，报18.08元/股，成交6532.98万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2023年年报，药明合联营业总收入21.24亿元、净利润2.84亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/13095440617148.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"1169344671","title":"医药突传重磅！药明康德迎转机？ 美药企合同豁免权或延长8年","url":"https://stock-news.laohu8.com/highlight/detail?id=1169344671","media":"券商中国","top":-1,"share":"https://www.laohu8.com/m/news/1169344671?lang=zh_cn&edition=full","pubTime":"2024-05-13 09:28","pubTimestamp":1715563702,"startTime":"0","endTime":"0","summary":"医药行业突然传来重磅消息！重磅传来新版国会法案将限制美国与包括药明康德和华大基因在内的某些中国生物科技公司开展业务，该法案将要求美国公司在2032年之前结束与这些公司的合作，从而延长寻找新合作伙伴的时间。因为这份《生物安全法案》，药明康德等生物医药巨头跌幅巨大。","market":"sh","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"gpt_icon":1},{"id":"2433366711","title":"药明合联05月08日获主力加仓2210万元 环比增加2355.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2433366711","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2433366711?lang=zh_cn&edition=full","pubTime":"2024-05-08 16:16","pubTimestamp":1715156178,"startTime":"0","endTime":"0","summary":"05月08日, 药明合联股价跌6.31%，报收18.42元，成交金额1.24亿元，换手率0.55%，振幅7.53%，量比2.08。药明合联今日主力资金净流入2210万元，连续7日净流入，上一交易日主力净流入90万元，今日环比增加2355.56%。该股近5个交易日下跌15.98%，主力资金累计净流入4837万元；近20日主力资金累计净流入5256万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405081617078ae7f7a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405081617078ae7f7a8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433796218","title":"药明合联(02268)下跌5.09%，报18.66元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2433796218","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2433796218?lang=zh_cn&edition=full","pubTime":"2024-05-08 13:01","pubTimestamp":1715144488,"startTime":"0","endTime":"0","summary":"5月8日，药明合联(02268)盘中下跌5.09%，截至13:01，报18.66元/股，成交6626.22万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2023年年报，药明合联营业总收入21.24亿元、净利润2.84亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/08130140561708.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433274761","title":"药明合联沽空率高企！锅圈、普乐师等公司迎来股份解禁","url":"https://stock-news.laohu8.com/highlight/detail?id=2433274761","media":"财华社","top":-1,"share":"https://www.laohu8.com/m/news/2433274761?lang=zh_cn&edition=full","pubTime":"2024-05-08 10:20","pubTimestamp":1715134854,"startTime":"0","endTime":"0","summary":"5月2日，锅圈（2517.HK）迎来基石投资者解禁，累计解禁3700.28万股，按4月30日的收盘价5.5港元计算，解禁的市值约2.035亿港元。","market":"us","thumbnail":"https://images.finet.hk/photoLib/title/202405_1/9b2ddb72-17cd-4990-a5b8-b53afb8aebf0.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202405_1/9b2ddb72-17cd-4990-a5b8-b53afb8aebf0.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/663ae186bde0b352c750471c","is_publish_highlight":false,"gpt_icon":0},{"id":"2433575260","title":"药明合联(02268)下跌5.26%，报19.8元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2433575260","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2433575260?lang=zh_cn&edition=full","pubTime":"2024-05-07 10:16","pubTimestamp":1715048208,"startTime":"0","endTime":"0","summary":"5月7日，药明合联(02268)盘中下跌5.26%，截至10:16，报19.8元/股，成交2769.5万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2023年年报，药明合联营业总收入21.24亿元、净利润2.84亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/07101640542173.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433469746","title":"【港股通】药明合联(02268)开盘涨超5% 机构指原材料采购协议上限大幅提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2433469746","media":"金吾资讯","top":-1,"share":"https://www.laohu8.com/m/news/2433469746?lang=zh_cn&edition=full","pubTime":"2024-05-06 09:37","pubTimestamp":1714959438,"startTime":"0","endTime":"0","summary":"金吾财讯 | 药明合联(02268)跳空高开，截至发稿，涨5.33%，报21.75港元，成交额555.84万港元。民生证券发研报指，药明合联日前发布公告，将2024年从药明生物的原材料采购服务协议上限从3260万元提高至8000万元（+145%），将2025年上限从2130万元提高至7500万元（+252%）。对药明生物的原材料需求进一步增长，采购服务协议的所有条款及条件均维持不变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050609374087d647c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050609374087d647c5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433466017","title":"药明合联(02268)上涨5.08%，报21.7元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2433466017","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2433466017?lang=zh_cn&edition=full","pubTime":"2024-05-06 09:31","pubTimestamp":1714959063,"startTime":"0","endTime":"0","summary":"5月6日，药明合联(02268)盘中上涨5.08%，截至09:31，报21.7元/股，成交204.29万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2023年年报，药明合联营业总收入21.24亿元、净利润2.84亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/06093140522066.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2432949623","title":"药明合联05月02日获主力加仓331万元 环比增加442.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432949623","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432949623?lang=zh_cn&edition=full","pubTime":"2024-05-02 16:16","pubTimestamp":1714637805,"startTime":"0","endTime":"0","summary":"05月02日, 药明合联股价涨5.25%，报收23.05元，成交金额2180万元，换手率0.08%，振幅7.53%，量比0.41。药明合联今日主力资金净流入331万元，连续3日净流入，上一交易日主力净流入61万元，今日环比增加442.62%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为33.33%，平均涨幅为2.67%。该股近5个交易日上涨21.71%，主力资金累计净流入655万元；近20日主力资金累计净流入1260万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405021617228b6c6046&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405021617228b6c6046&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432413226","title":"药明合联(02268)上涨5.25%，报23.05元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2432413226","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2432413226?lang=zh_cn&edition=full","pubTime":"2024-05-02 15:05","pubTimestamp":1714633508,"startTime":"0","endTime":"0","summary":"5月2日，药明合联(02268)盘中上涨5.25%，截至15:05，报23.05元/股，成交1323.17万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2023年年报，药明合联营业总收入21.24亿元、净利润2.84亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/02150540509898.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2432448476","title":"药明合联(02268)股价上升5.023%，现价港币$23.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2432448476","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2432448476?lang=zh_cn&edition=full","pubTime":"2024-05-02 15:05","pubTimestamp":1714633500,"startTime":"0","endTime":"0","summary":"[上升股]药明合联(02268) 股价在下午03:05比前收市价上升5.023%，现股价为港币$23.0。至目前为止，今日最高价为$23.0，而最低价为$21.55。总成交量为57.977万股，总成交金额为港币$1.307千万。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2405024698/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2432431236","title":"【港股通】药明合联(02268)涨逾3% 民生证券指其业绩持续高增 维持“推荐”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2432431236","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2432431236?lang=zh_cn&edition=full","pubTime":"2024-05-02 14:02","pubTimestamp":1714629739,"startTime":"0","endTime":"0","summary":"金吾财讯 | 药明合联 震荡走高，截至发稿，涨3.20%，报22.6港元，成交额946.2万港元。民生证券发研报指，公司公告，将2024年从药明生物的原材料采购服务协议上限提升145%，将2025年上限提升252%。该行表示，药明合联是全球领先的一站式ADCCRDMO龙头，业绩持续高增长，下游客户需求保持强劲，该行预计2024-2026年公司实现营业收入32.00/47.03/67.26亿元，同比增长50.7%/47.0%/43.0%，归母净利润5.62/9.10/13.71亿元，对应PE为43/27/18倍，维持“推荐”评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/MDE2Mjg1ODkyMTQzNDI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MDE2Mjg1ODkyMTQzNDI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1936160","is_publish_highlight":false,"gpt_icon":0},{"id":"2431546933","title":"【券商聚焦】民生证券指药明合联(02268)大幅提升原材料采购协议上限 维持“推荐”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2431546933","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2431546933?lang=zh_cn&edition=full","pubTime":"2024-04-30 14:13","pubTimestamp":1714457617,"startTime":"0","endTime":"0","summary":"金吾财讯 | 民生证券发研报指，药明合联 发布公告，将2024年从药明生物的原材料采购服务协议上限从3260万元提高至8000万元，将2025年上限从2130万元提高至7500万元。对药明生物的原材料需求进一步增长，采购服务协议的所有条款及条件均维持不变。该行续指，药明合联是全球领先的一站式ADCCRDMO龙头，业绩持续高增长，下游客户需求保持强劲，该行预计2024-2026年公司实现营业收入32.00/47.03/67.26亿元，同比增长50.7%/47.0%/43.0%，归母净利润5.62/9.10/13.71亿元，对应PE为43/27/18倍，维持“推荐”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/ZmQxNzMzMGZkNTNkZDQwNzE0NzM5MzEwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZmQxNzMzMGZkNTNkZDQwNzE0NzM5MzEwNQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1936084","is_publish_highlight":false,"gpt_icon":0},{"id":"2431008139","title":"药明合联(02268)股价上升8.293%，现价港币$22.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2431008139","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2431008139?lang=zh_cn&edition=full","pubTime":"2024-04-29 14:34","pubTimestamp":1714372440,"startTime":"0","endTime":"0","summary":"[上升股]药明合联(02268) 股价在下午02:34比前收市价上升8.293%，现股价为港币$22.2。至目前为止，今日最高价为$22.2，而最低价为$20.8。总成交量为295.665万股，总成交金额为港币$6.358千万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2404293927/aamm-all-category","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://wuxixdc.com","stockEarnings":[{"period":"1week","weight":-0.1102},{"period":"1month","weight":-0.0309},{"period":"3month","weight":0.168},{"period":"6month","weight":-0.3943},{"period":"1year","weight":-0.1767},{"period":"ytd","weight":-0.47}],"compareEarnings":[{"period":"1week","weight":0.0311},{"period":"1month","weight":0.2032},{"period":"3month","weight":0.1967},{"period":"6month","weight":0.1203},{"period":"1year","weight":-0.0088},{"period":"ytd","weight":0.147}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"WuXi XDC Cayman Inc是一家主要从事提供抗体偶联药物（ADC）及更广泛生物偶联药物的合同研究、开发和生产服务（CRDMO）的控股公司。该公司通过两个分部开展其业务。按有偿服务基准的研究服务分部透过有偿服务合约向客户提供研究服务。按全时当量基准提供的研究服务分部提供一个项目小组，该小组的员工在特定时间内专门负责客户的研究。基于生物药和小分子药物，该公司还提供跨领域的综合服务，涵盖生物偶联药物及连接子及有效载荷的发现、工艺开发及药品生产质量管理规范（GMP）生产。该公司在国内外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.222222,"avgChangeRate":0.010265},{"month":2,"riseRate":0.666667,"avgChangeRate":0.058284},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.010372},{"month":4,"riseRate":0.555556,"avgChangeRate":0.03555},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006014},{"month":6,"riseRate":0.4,"avgChangeRate":-0.032735},{"month":7,"riseRate":0.4,"avgChangeRate":0.011785},{"month":8,"riseRate":0.4,"avgChangeRate":-0.114063},{"month":9,"riseRate":0.333333,"avgChangeRate":0.019767},{"month":10,"riseRate":0.777778,"avgChangeRate":0.151657},{"month":11,"riseRate":0.333333,"avgChangeRate":0.008796},{"month":12,"riseRate":0.111111,"avgChangeRate":-0.068876}],"exchange":"SEHK","name":"药明合联","nameEN":"WUXI XDC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明合联,02268,药明合联股票,药明合联股票老虎,药明合联股票老虎国际,药明合联行情,药明合联股票行情,药明合联股价,药明合联股市,药明合联股票价格,药明合联股票交易,药明合联股票购买,药明合联股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}